Stock Events

Bluebird bio 

$1.16
143
+$0+0% Today

Statistics

Day High
1.25
Day Low
1.16
52W High
5.53
52W Low
0.89
Volume
20,290
Avg. Volume
57,271
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

26MarConfirmed
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Q4 2023
-1.66
-1.25
-0.85
-0.44
Expected EPS
-0.66
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0HOH.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.63B
CRISPR Therapeutics is directly competing in the gene editing space, focusing on similar therapeutic areas as Bluebird bio, including hemoglobinopathies.
Sangamo Therapeutics
SGMO
Mkt Cap82.4M
Sangamo Therapeutics specializes in genomic medicine, using gene therapy to target conditions that overlap with Bluebird bio's focus areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals is involved in treating cystic fibrosis and other diseases, competing in the gene therapy market where Bluebird bio is also aiming to make an impact.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.97B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and gene therapies for rare genetic disorders, directly competing with Bluebird bio's gene therapy approach.
Intellia Therapeutics
NTLA
Mkt Cap2.42B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, targeting diseases in a similar manner to Bluebird bio.
Editas Medicine
EDIT
Mkt Cap411.19M
Editas Medicine operates in the gene editing sector, focusing on delivering precise genomic modifications, competing with Bluebird bio's gene therapy strategies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.08B
Alnylam Pharmaceuticals is pioneering RNA interference (RNAi) therapies, which, while a different approach, target some of the same diseases as Bluebird bio.
Beam Therapeutics
BEAM
Mkt Cap2.14B
Beam Therapeutics is advancing the field of gene editing with base editing technology, a direct competitor to Bluebird bio's gene therapy and editing efforts.
Pfizer
PFE
Mkt Cap169.83B
Pfizer, with its broad interest in biopharmaceuticals, including gene therapy, competes across several areas, including those targeted by Bluebird bio.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space, particularly in oncology, overlapping with Bluebird bio's cancer therapy efforts.

About

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Andrew Obenshain
Employees
518
Country
United States
ISIN
US09609G1004

Listings